WINNIPEG, Jan. 6 /CNW/ - (TSX: IM) -- IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced the sale of IMRISneuro to Orlando based, Florida Hospital.
Florida Hospital is the largest hospital system in the state of Florida with eighteen campuses. It has one of the most comprehensive neuroscience facilities in the U.S. southeast, offering a number of programs and services to address an array of neurological and spinal disorders including brain tumors, strokes, Parkinson's disease, as well as disc disease and sleep disorders.
The IMRISneuro system at Florida Hospital Orlando will include a wide bore 3 Tesla MR scanner operating in a three room configuration that will provide tremendous capacity for intra operative MR imaging on demand in either of two operating theatres. As well, when not in use for intra operative imaging, the MR scanner is available for diagnostic imaging.
"Having this MRI will help improve outcomes for our surgical patients," said Dr. Melvin Field, Florida Hospital neurosurgeon and surgical director of Florida Hospital Cancer Institute Brain and Spine Tumor Program. "For the first time, it will enable us to ensure that we have completely removed brain tumors prior to the patients leaving the operating room."
No other system offers the same degree of safety for both the patient and the surgical environment. IMRISneuro does not require the patient to be transported for scanning, so the optimum position for neurosurgery is never compromised. Clinical workflow and surgical access to the patient is not impacted and the magnet is removed completely from the operating room when scanning is complete. IMRISneuro provides neurosurgeons with timely images during surgery from which they are able to make better decisions for their patients.
IMRIS (TSX: IM) is a global leader in providing image guided therapy solutions. These solutions feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets and have been selected by leading medical institutions around the world.
SOURCE IMRIS Inc.
For further information: For further information: Brad Woods, Director Investor Relations & Corporate Communications, IMRIS Inc., Tel: (204) 480-7094, Email: email@example.com